Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: unintentional (5), unintended (5), inadvertent (4), chance (293), unplanned (35), fortuitous (1)

Appendix D - HBIG 500 IU NSI risk assessment and prescription form

Description: Accidental exposure to blood or other body fluids: risk assessment for post-exposure prophylaxis (PEP) with Hepatitis B Immunoglobulin (HBIG) and
Url: /Media/UHS-website-2019/Docs/Post-Exposure-Prophylaxis-Policy/AppendixD-HBIG500IUNSIRiskAssessmentandPrescriptionForm.pdf

Eye injuries in children - patient information

Description: This factsheet highlights some of the common causes of eye injuries, ways to prevent eye injuries and what you can do
Url: /Media/UHS-website-2019/Patientinformation/Eyes/Eye-injuries-in-children-2362-PIL.PDF

Axicel-Cyclophosphamide(500)-Fludarabine(30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be available to pres
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Axicel-Cyclophosphamide500-Fludarabine30.pdf

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Ambulatory Regimen This regimen is for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) This regimen will only be available to presc
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) Ambulatory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

Data protection and confidentiality policy

Description: University Hospitals Southampton NHS Foundation Trust needs to collect and use information about people with whom it deals in order to
Url: /Media/UHS-website-2019/Docs/Policies/Data-protection-and-confidentiality-policy.pdf

ACCORD-2 master protocol

Description: CONFIDENTIAL ACCORD-2-001 – Master Protocol TITLE PAGE Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-master-protocol.pdf

Spinal cord stimulator implantation aftercare advice - patient information

Description: This factsheet explains what to expect after having surgery to implant a spinal cord stimulator and how to recover well at
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Spinal-cord-stimulator-implantation-aftercare-advice-4075-PIL.pdf

Systemic anti-cancer therapy (SACT) extravasation - patient information

Description: This factsheet explains what systemic anti-cancer therapy (SACT) extravasation is, what causes it and the signs you need to be
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Systemic-anti-cancer-therapy-SACT-extravasation-3918-PIL.pdf

1 to 10 of 30

Previous 1 2 3 Next